Overview
NAD+ / MOTS-c / 5-Amino-1MQ is a mitochondrial and metabolic stack concept built around cellular energy handling. Direct NAD+ provides the redox cofactor itself, MOTS-c targets mitochondrial stress-response signaling, and 5-Amino-1MQ targets NNMT-linked nicotinamide metabolism. [1][3][4][8]
The biochemical rationale is coherent, but this is not a validated human longevity protocol. Direct compounded NAD+, MOTS-c, and 5-Amino-1MQ sit at very different evidence levels. [2][5][9]
Peptides in this stack
NAD+
Redox/NAD metabolism compound
Direct NAD+—not NMN or NR—with exact compounded vial, nasal-spray, and metered topical presets and limited route-matched human evidence.
MOTS-c
Mitochondrial peptide
A mitochondria-derived peptide linked to metabolic stress signaling, AMPK biology, and exercise adaptation, with early human activity but limited outcome data.
5-Amino-1MQ
Redox/NAD metabolism compound
A selective NNMT inhibitor studied for fat-mass and NAD+ metabolism, with mouse data and mechanistic rationale but no published human outcome trial.
Why They're Combined
The stack is built around energy metabolism from three angles. Direct NAD+ supplies the cofactor itself, MOTS-c is a mitochondrial-derived peptide linked with metabolic stress signaling, and 5-Amino-1MQ is discussed as an NNMT inhibitor that may affect nicotinamide handling and adipose metabolism. [1][3][4][7][8]
The practical idea is not one longevity lever. It is a direct NAD+ layer, a mitochondrial signaling layer, and a metabolic-enzyme layer. That makes the stack conceptually organized, but still highly dependent on each component's evidence quality. [2][6][9]
How They Work Together
The proposed mechanism starts with NAD+ as a cellular cofactor for redox and signaling biology. MOTS-c adds a mitochondrial stress-response and exercise-linked signaling rationale, while 5-Amino-1MQ targets NNMT, an enzyme connected to nicotinamide metabolism and adipose energy handling. [1][4][6][7]
In plain terms, the stack tries to connect energy availability, mitochondrial adaptation, and metabolic enzyme signaling. That makes it conceptually tighter than a loose longevity mix, but the mechanism still has to survive real human testing as a combination. [2][5][9]
What the Evidence Shows
Direct NAD+ has only early human administration research and compounded-product references in this stack. MOTS-c has human biomarker and exercise-context literature plus substantial mechanistic work. 5-Amino-1MQ remains much more preclinical, with animal and NNMT-target literature doing most of the work. [1][2][5][3][8][9]
No controlled human trial establishes this three-part stack for longevity, fat loss, insulin sensitivity, mitochondrial function, or exercise performance. The combination should be treated as a mechanistic stack with uneven evidence, not a validated metabolic protocol. [2][5][9]
Typical Protocol
The selected direct NAD+ preset uses 50 mg subcutaneously on Monday, Wednesday, and Friday for 30 days. Common MOTS-c injectable protocols use 5-10 mg per dose, often morning or pre-workout. Common 5-Amino-1MQ oral protocols use 50-100 mg once daily, usually in the morning. [3][8]
A clean tracking plan places direct NAD+ and MOTS-c on their fixed injection days, keeps 5-Amino-1MQ daily, and reviews the NAD+ component after its 30-day window. Weight, waist, fasting glucose, exercise capacity, sleep, appetite, and tolerance are practical tracking points. [6][9]
Important Considerations
The evidence is uneven across the three components. Direct NAD+ has limited route-matched human data, MOTS-c is much less translated, and 5-Amino-1MQ is still highly experimental. NMN and NR evidence is not interchangeable with injectable NAD+, so molecule, route, form, and evidence level need to stay separate. [1][2]
The stack can become noisy quickly because diet, training, sleep, fasting, glucose status, and body weight all affect the same outcomes. Product identity and stability matter for all three components, and glucose-lowering medications or aggressive calorie restriction can change the risk profile. Change one variable at a time if the goal is to learn anything from the protocol. [2][5][9]
Published research 9 sources
A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD
Frontiers in Aging Neuroscience, 2019-09-12. human clinical.
Absorption and Tolerability of Injectable Administration of Niagen+, as Compared to NAD+
ClinicalTrials.gov. clinical trial registry.
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
Cell metabolism, 2015 Mar 3. in vitro.
The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.
Cell metabolism, 2018 Sep 4. in vitro.
Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans.
Journal of applied physiology (Bethesda, Md. : 1985), 2021 Sep 1. human clinical.
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
Nature communications, 2021 Jan 20. review.
Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.
Nature, 2014 Apr 10. review.
Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.
Biochemical pharmacology, 2018 Jan. animal.
Exploring NNMT: from metabolic pathways to therapeutic targets.
Archives of pharmacal research, 2024 Dec. review.